Urocortin-3
Also known as: UCN3, Urocortin III, stresscopin, SCP
Neuropeptide; member of the corticotropin-releasing factor (CRF) peptide family; selective agonist of CRF receptor type 2 (CRHR2)
What it is
Researchers studying stress responses, pancreatic function, reproductive biology, and gut health have investigated urocortin-3. Found naturally in the brain, pancreas, and other tissues, it acts on a specific stress-hormone receptor and is of interest for its potential roles in anxiety, insulin regulation, and PTSD-related pathways.
The scientific side
urocortin-3 (UCN3) is a peptide belonging to the corticotropin-releasing hormone (CRH) family and functions as a highly selective agonist of CRH receptor type 2 (CRHR2). Unlike CRH itself, which preferentially binds CRHR1 and exerts anxiogenic effects, UCN3 binding to CRHR2 produces downstream effects that are generally modulatory or anxiolytic in character, though the directionality is dose- and region-dependent. In the central nervous system, UCN3-expressing neurons are concentrated in the posterodorsal medial amygdala (MePD) and the perifornical hypothalamic area. Within the MePD, UCN3 neurons interact with two anti-correlated GABAergic subpopulations to regulate gonadotropin-releasing hormone (GnRH) pulse frequency, providing a direct mechanistic link between stress signaling and reproductive axis suppression (PMID 41807404). In the hypothalamus, UCN3 neurons in the perifornical area are influenced by perinatal stress exposure and express mineralocorticoid receptors, implicating them in stress-induced alterations to maternal behavior (PMIDs 42845798, 41253068, 41240774). In pancreatic islets, UCN3 is released by beta cells at high glucose concentrations to stimulate adjacent delta cells via paracrine signaling, creating a negative feedback loop that suppresses further insulin and glucagon secretion through somatostatin release; this paracrine circuit is partially mediated by Connexin 36 gap junctions and vesicular release (PMID 40956879). In a PTSD animal model, intranasal administration of UCN3 reversed stress-induced anxiety-like behavior and normalized FKBP5 and glucocorticoid receptor mRNA expression in the paraventricular nucleus (PVN) and bed nucleus of the stria terminalis (BNST), indicating effects on HPA axis gene regulation (PMID 39595978). UCN3 acting via CRHR2 also modulates the splenic microbiota-immune-brain axis in a single prolonged stress model, preventing stress-induced dysbiosis of Enterobacteriaceae and Lactobacillus and restoring hippocampal neuroinflammatory marker expression (PMID 42617550). In the intestine, CRHR2 activation inhibits angiogenesis and reduces colitis severity, with UCN3 (as a specific CRHR2 agonist) showing opposite effects to CRH on endothelial cell behavior (PMID 20206175). In the ovary, UCN3 is expressed in granulosa-lutein cells and suppresses progesterone production through CRHR2 at nanomolar concentrations (PMID 19351656).
Class: Neuropeptide; member of the corticotropin-releasing factor (CRF) peptide family; selective agonist of CRF receptor type 2 (CRHR2)
Administration & storage
- Administration
- Intracerebroventricular (ICV) — rodent studies only (PMID 2393230821185316)Intranasal — rodent studies only (PMIDs 3959597842617550)In vitro peptide addition to cell culture media (PMID 1935165620206175)
- Storage
- No storage data for formulated UCN3 reported in the fetched human-use literature. Peptides of this class are generally stored lyophilized at low temperature in research settings.
Legal & regulatory status
Not approved for any therapeutic indication in humans. No FDA-regulated clinical trials specifically testing urocortin-3 as a therapeutic agent were identified. Research use only. (No PMIDs directly address FDA status;…
Not explicitly listed as a prohibited substance in the available published abstracts. No WADA-relevant competitive performance data identified in fetched literature.
No approved indication identified. Not reviewed for therapeutic use in Canada based on available literature.
What it's studied for
- PTSD and anxiety-like behavior (preclinical) Preclinical — rodent models only
- Pancreatic islet paracrine regulation and insulin secretion feedback Preclinical — in vitro and ex vivo
- Stress-induced reproductive suppression (neuroendocrine axis) Preclinical — rodent models only
- Maternal behavior and perinatal stress responses Preclinical — rodent models only
- HPA axis modulation and CRF system regulation Preclinical — rodent in vivo and ex vivo
- Intestinal inflammation and angiogenesis Preclinical — rodent models and in vitro
- Ovarian steroidogenesis and progesterone suppression Preclinical — human primary cell culture
- Parkinson's disease and neurodegeneration (exploratory) Preclinical — rodent model only
Safety signals
- Bidirectional and dose-dependent effects on HPA axis (corticosterone elevation at some doses)
- Suppression of progesterone production in ovarian granulosa-lutein cells
- Stress-induced suppression of reproductive axis (LH pulse frequency reduction)
- Inhibition of intestinal angiogenesis and alteration of intestinal inflammation
- Modulation of microbiota and splenic immune markers
- Sensorimotor gating: ICV urocortin III did not replicate stress-induced PPI deficit, but CRF2 blockade attenuated it
- No human safety data available
All studies (7)
Frequently asked
What does urocortin-3 actually do in the body?
Based on published preclinical research, urocortin-3 is a naturally occurring peptide that binds selectively to CRH receptor type 2 (CRHR2). It is found in brain regions that regulate stress responses (including the amygdala and hypothalamus), in pancreatic beta cells where it helps fine-tune insulin and glucagon secretion via a paracrine feedback loop, and in reproductive tissues where it can suppress progesterone production. Its effects are highly context-dependent and differ based on dose, brain region, and whether an animal is under stress. No human therapeutic data are available.
Has urocortin-3 been tested in humans?
As of the available published literature and a ClinicalTrials.gov search, no interventional human clinical trials using urocortin-3 as an administered therapeutic agent have been identified. All current evidence comes from rodent studies, cell culture experiments, and genetic association studies. Urocortin-3 has no FDA-approved indication and should be considered research-stage only.
Can urocortin-3 help with PTSD or anxiety?
Preclinical rodent studies using intranasal UCN3 in single prolonged stress (SPS) models have shown reversal of some anxiety-like behavioral measures and normalization of stress-related gene expression in the brain. These are promising early signals, but no human trials have tested UCN3 for PTSD or anxiety. Extrapolating rodent results to human benefit is not currently supported by evidence.
What is the connection between urocortin-3 and diabetes or insulin?
Research in pancreatic islets shows that beta cells release UCN3 at high glucose concentrations to stimulate neighboring delta cells, which then release somatostatin — a hormone that limits further insulin and glucagon secretion. This paracrine feedback loop helps prevent excessive insulin release. UCN3 expression in beta cells is also reduced in certain genetic models of diabetes. GLP-1 signaling (relevant to GLP-1 receptor agonist medications) also modulates UCN3 as one pathway involved in insulin exocytosis. These are mechanistic findings in research models, not clinical guidance.
Is urocortin-3 banned in sport?
The fetched literature does not contain any WADA classification for urocortin-3, and no evidence of performance enhancement in athletic contexts was identified. Given the absence of human data, a definitive WADA status cannot be confirmed from available evidence. Athletes should consult current WADA prohibited list documentation directly.
What dose of urocortin-3 was used in studies?
Published preclinical studies used intracerebroventricular injections of 0.5–5 µg in rats, or intranasal administration in rodent PTSD models (exact doses not specified in available abstracts). In cell culture, concentrations of 0.1–10 nM were used to study progesterone suppression in human granulosa cells. None of these translate to human dosing guidance, and no human pharmacokinetic data exist.